Skip to main content
Article thumbnail
Location of Repository

Intravenous tPA therapy does not worsen acute intracerebral hemorrhage in mice

By Christian Förch, Nathanael L. Rosidi, Frieder Schlunk, Arne Lauer, Flor A. Cianchetti, Emiri Mandeville, Ken Arai, Kazim Yigitkanli, Xiang Fan, Xiaoying Wang, Klaus van Leyen, Helmuth Steinmetz, Chris B. Schaffer and Eng H. Lo

Abstract

Tissue plasminogen activator (tPA) is the only FDA-approved treatment for reperfusing ischemic strokes. But widespread use of tPA is still limited by fears of inadvertently administering tPA in patients with intracerebral hemorrhage (ICH). Surprisingly, however, the assumption that tPA will worsen ICH has never been biologically tested. Here, we assessed the effects of tPA in two models of ICH. In a mouse model of collagenase-induced ICH, hemorrhage volumes and neurological deficits after 24 hrs were similar in saline controls and tPA-treated mice, whereas heparin-treated mice had 3-fold larger hematomas. In a model of laser-induced vessel rupture, tPA also did not worsen hemorrhage volumes, while heparin did. tPA is known to worsen neurovascular injury by amplifying matrix metalloproteinases during cerebral ischemia. In contrast, tPA did not upregulate matrix metalloproteinases in our mouse ICH models. In summary, our experimental data do not support the assumption that intravenous tPA has a deleterious effect in acute ICH. However, due to potential species differences and the inability of models to fully capture the dynamics of human ICH, caution is warranted when considering the implications of these findings for human therapy

Topics: ddc:610
Year: 2013
OAI identifier: oai:publikationen.ub.uni-frankfurt.de:28889

Suggested articles

Citations

  1. (2008). A new grading system evaluating bleeding scale in filament perforation subarachnoid hemorrhage rat model.
  2. (2006). Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage.
  3. (2010). Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke.
  4. (1990). Collagenaseinduced intracerebral hemorrhage in rats.
  5. (2009). Comparison of experimental rat models of early brain injury after subarachnoid hemorrhage.
  6. (1989). Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis.
  7. (2010). Exacerbation of perihematomal edema and sterile meningitis with intraventricular administration of tissue plasminogen activator in patients with intracerebral hemorrhage.
  8. (2008). Experimental model of warfarin-associated intracerebral hemorrhage.
  9. (2007). Guidelines for the early management of adults with ischemic stroke.
  10. (2006). How does spontaneous hemostasis occur in ruptured cerebral aneurysms? Preliminary investigation on 247 clipping surgeries.
  11. (2010). Inhibition of reactive astrocytes with fluorocitrate retards neurovascular remodeling and recovery after focal cerebral ischemia in mice.
  12. (1997). Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke.
  13. (2003). Lipoprotein receptormediated induction of matrix metalloproteinase-9 in human cerebral endothelial cells.
  14. (2012). Memantine Improves Safety of Thrombolysis for Stroke.
  15. (2000). Mortality and prehospital thrombolysis for acute myocardial infarction: A metaanalysis.
  16. (2002). Mouse models in coagulation.
  17. (2006). Neutralizing the neurotoxic effects of exogenous and endogenous tPA.
  18. (2007). Penetrating arterioles are a bottleneck in the perfusion of neocortex.
  19. (2005). Prohemorrhagic and Bleeding Time Activities of Recombinant Tissue Plasminogen Activator, Heparin, Aspirin, and a Glycoprotein IIb/IIIa Antagonist.
  20. (2001). Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery.
  21. (1980). Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning.
  22. (2009). Relative importance of proteinase-activated receptor-1 versus matrix metalloproteinases in intracerebral hemorrhage-mediated neurotoxicity in mice.
  23. (2000). Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94.
  24. (2009). Role of interleukin-1beta in early brain injury after subarachnoid hemorrhage in mice.
  25. (2006). Targeted insult to subsurface cortical blood vessels using ultrashort laser pulses: three models of stroke.
  26. (1989). The molecular basis of thrombolysis and its clinical application in stroke.
  27. (2004). The role of endogenous versus exogenous tPA on edema formation in murine ICH.
  28. (2005). Tissue plasminogen activator mediated blood-brain barrier damage in transient focal cerebral ischemia in rats: relevance of interactions between thrombotic material and thrombolytic agent.
  29. (1985). Tissue plasminogen activator reduces neurological damage after cerebral embolism.
  30. (2003). Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein.
  31. (2006). Two-photon imaging of cortical surface microvessels reveals a robust redistribution in blood flow after vascular occlusion.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.